ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: House Appropriations Bill Marked Up, Lid Clamped On; Wells Named DCT Board Chairman

July 6, 1984

Only Three Of 28 CCRU, CCSP Proposals Approved, But DRCCA Will Try Again, Board OKs New RFAs

May 13, 1983

In Brief: Gallo Signs Agreement With Univ. of Maryland; Donor Gives $5 Million To San Diego Center

May 26, 1995

Healy’s Boxes Packed, When Word Came That She Could Stay

January 29, 1993

Howard Hughes Medical Institute Appoints 12 Physician Investigators

May 31, 2002

Cancer Patients Satisfied With Experience In Clinical Trials, Survey Of 2,000 Finds

July 28, 2006